Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Bellizzi

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Surgical Oncology Clinics of North America|March 11, 2020
Pathologic Considerations in Gastroenteropancreatic Neuroendocrine TumorsAndrew M Bellizzi
American Journal of Clinical Pathology|February 20, 2015
Screening for Lynch syndrome: a no-brainer: BRAF V600E mutation-specific immunohistochemistry: caveat emptorAndrew M Bellizzi
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 20, 2023
p53 as Exemplar Next-Generation Immunohistochemical Marker: A Molecularly Informed, Pattern-Based Approach, Methodological Considerations, and Pan-Cancer Diagnostic ApplicationsAndrew M Bellizzi
Advances in Anatomic Pathology|August 14, 2013
Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistryAndrew M Bellizzi
Advances in Anatomic Pathology|March 25, 2020
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of OriginAndrew M Bellizzi
Seminars in Diagnostic Pathology|December 18, 2013
Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasmsAndrew M Bellizzi
Surgical Pathology Clinics|February 4, 2016
Immunohistochemistry in Gastroenterohepatopancreatobiliary Epithelial Neoplasia: Practical Applications, Pitfalls, and Emerging MarkersAndrew M Bellizzi
Human Pathology|December 21, 2019
Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?Andrew M Bellizzi
Histopathology|June 25, 2019
SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomasAndrew M Bellizzi
American Journal of Clinical Pathology|November 15, 2013
Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinomaMichael P Gailey, Andrew M Bellizzi
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Surgical Oncology Clinics of North America|March 11, 2020
Pathologic Considerations in Gastroenteropancreatic Neuroendocrine TumorsAndrew M Bellizzi
American Journal of Clinical Pathology|February 20, 2015
Screening for Lynch syndrome: a no-brainer: BRAF V600E mutation-specific immunohistochemistry: caveat emptorAndrew M Bellizzi
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 20, 2023
p53 as Exemplar Next-Generation Immunohistochemical Marker: A Molecularly Informed, Pattern-Based Approach, Methodological Considerations, and Pan-Cancer Diagnostic ApplicationsAndrew M Bellizzi
Advances in Anatomic Pathology|August 14, 2013
Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistryAndrew M Bellizzi
Advances in Anatomic Pathology|March 25, 2020
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of OriginAndrew M Bellizzi
Seminars in Diagnostic Pathology|December 18, 2013
Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasmsAndrew M Bellizzi
Surgical Pathology Clinics|February 4, 2016
Immunohistochemistry in Gastroenterohepatopancreatobiliary Epithelial Neoplasia: Practical Applications, Pitfalls, and Emerging MarkersAndrew M Bellizzi
Human Pathology|December 21, 2019
Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?Andrew M Bellizzi
Histopathology|June 25, 2019
SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomasAndrew M Bellizzi
American Journal of Clinical Pathology|November 15, 2013
Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinomaMichael P Gailey, Andrew M Bellizzi
Pageof 16